Sándor Szalma

Sándor Szalma

Auto-generated profile, based on publicly available information

Sándor Szalma

Takeda Development Center Americas, Inc

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2023 in Nature
Verified
Journal Article
Open access
PDF file
BSBenjamin B. Sun
Benjamin B. Sun
JCJoshua Chiou
Joshua Chiou
MTMatthew Traylor
Matthew Traylor
CBChristian Benner
Christian Benner
YHYi-Hsiang Hsu
Yi-Hsiang Hsu
CWChristopher D. Whelan
Christopher D. Whelan
The Pharma Proteomics Project is a precompetitive biopharmaceutical consortium characterizing the plasma proteomic profiles of 54,219 UK Biobank participants. Here we provide a detailed summary of this initiative, including technical and biological validations, insights into proteomic disease signatures, and prediction modelling for various demographic and health indicators. We present comprehensive protein quantitative trait locus (pQTL) mapping of 2,923 proteins that identifies 14,287 primary genetic associations, of which 81% are previously undescribed, alongside ancestry-specific pQTL mapping in non-European individuals. The study provides an updated characterization of the genetic architecture of the plasma proteome, contextualized with projected pQTL discovery rates as sample sizes and proteomic assay coverages increase over time. We offer extensive insights into trans pQTLs across multiple biological domains, highlight genetic influences on ligand–receptor interactions and pathway perturbations across a diverse collection of cytokines and complement networks, and illustrate long-range epistatic effects of ABO blood group and FUT2 secretor status on proteins with gastrointestinal tissue-enriched expression. We demonstrate the utility of these data for drug discovery by extending the genetic proxied effects of protein targets, such as PCSK9, on additional endpoints, and disentangle specific genes and proteins perturbed at loci associated with COVID-19 susceptibility. This public–private partnership provides the scientific community with an open-access proteomics resource of considerable breadth and depth to help to elucidate the biological mechanisms underlying proteo-genomic discoveries and accelerate the development of biomarkers, predictive models and therapeutics1.

28 June 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JSJoseph D. Szustakowski
Joseph D. Szustakowski
SBSuganthi Balasubramanian
Suganthi Balasubramanian
EKErika Kvikstad
Erika Kvikstad
SKShareef Khalid
Shareef Khalid
PBPaola G. Bronson
Paola G. Bronson
JRJeffrey G. Reid
Jeffrey G. Reid

1 October 2015 in Cell Systems
Verified
Journal Article
Closed access
DPDexter Pratt
Dexter Pratt
JCJing Chen
Jing Chen
DWDavid Welker
David Welker
RRRicardo Rivas
Ricardo Rivas
RPRudolf Pillich
Rudolf Pillich
TITrey Ideker
Trey Ideker

1 February 2010 in OMICS: A Journal of Integrative Biology
Verified
Journal Article
Closed access
MSMichael Seiler
Michael Seiler
CHC. Chris Huang
C. Chris Huang
SSSandor Szalma
Sandor Szalma
GBGyan Bhanot
Gyan Bhanot
We have created a stand-alone software tool, ConsensusCluster, for the analysis of high-dimensional single nucleotide polymorphism (SNP) and gene expression microarray data. Our software implements the consensus clustering algorithm and principal component analysis to stratify the data into a given number of robust clusters. The robustness is achieved by combining clustering results from data and sample resampling as well as by averaging over various algorithms and parameter settings to achieve accurate, stable clustering results. We have implemented several different clustering algorithms in the software, including K-Means, Partition Around Medoids, Self-Organizing Map, and Hierarchical clustering methods. After clustering the data, ConsensusCluster generates a consensus matrix heatmap to give a useful visual representation of cluster membership, and automatically generates a log of selected features that distinguish each pair of clusters. ConsensusCluster gives more robust and more reliable clusters than common software packages and, therefore, is a powerful unsupervised learning tool that finds hidden patterns in data that might shed light on its biological interpretation. This software is free and available from http://code.google.com/p/consensus-cluster .

19 July 2010 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
SSSándor Szalma
Sándor Szalma
VKVenkata Koka
Venkata Koka
TKTatiana Khasanova
Tatiana Khasanova
EPEric D Perakslis
Eric D Perakslis
The growing consensus that most valuable data source for biomedical discoveries is derived from human samples is clearly reflected in the growing number of translational medicine and translational sciences departments across pharma as well as academic and government supported initiatives such as Clinical and Translational Science Awards (CTSA) in the US and the Seventh Framework Programme (FP7) of EU with emphasis on translating research for human health.

18 June 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
BSBenjamin B. Sun
Benjamin B. Sun
JCJoshua Chiou
Joshua Chiou
MTMatthew Traylor
Matthew Traylor
CBChristian Benner
Christian Benner
YHYi-Hsiang Hsu
Yi-Hsiang Hsu
CWChristopher D. Whelan
Christopher D. Whelan
The UK Biobank Pharma Proteomics Project (UKB-PPP) is a collaboration between the UK Biobank (UKB) and thirteen biopharmaceutical companies characterising the plasma proteomic profiles of 54,306 UKB participants. Here, we describe results from the first phase of UKB-PPP, including protein quantitative trait loci (pQTL) mapping of 1,463 proteins that identifies 10,248 primary genetic associations, of which 85% are newly discovered. We also identify independent secondary associations in 92% of cis and 29% of trans loci, expanding the catalogue of genetic instruments for downstream analyses. The study provides an updated characterisation of the genetic architecture of the plasma proteome, leveraging population-scale proteomics to provide novel, extensive insights into trans pQTLs across multiple biological domains. We highlight genetic influences on ligand-receptor interactions and pathway perturbations across a diverse collection of cytokines and complement proteins, and illustrate long-range epistatic effects of ABO blood group and FUT2 secretor status on proteins with gastrointestinal tissue-enriched expression. We demonstrate the utility of these data for drug target discovery by extending the genetic proxied effect of PCSK9 levels on lipid concentrations, cardio- and cerebro-vascular diseases, and additionally disentangle specific genes and proteins perturbed at COVID-19 susceptibility loci. This public-private partnership provides the scientific community with an open-access proteomics resource of unprecedented breadth and depth to help elucidate biological mechanisms underlying genetic discoveries and accelerate the development of novel biomarkers and therapeutics.